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Available online 3 January 2016Spinocerebellar ataxia type 2 (SCA2) is a neurodegenerative disease primarily affecting the cerebellum.Very little
is known about the molecular mechanisms underlying the disease and, to date, no cure or treatment is available.
We have successfully generated bona ﬁde induced pluripotent stem cell (iPSC) lines of SCA2 patients in order to
study a disease-speciﬁc phenotype. Here, we demonstrate the gene correction of the iPSC line H196 clone 7
where we have exchanged the expanded CAG repeat of the ATXN2 genewith the normal length found in healthy
alleles. This gene corrected cell line will provide the ideal control to model SCA2 by iPSC technology.
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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An induced pluripoten stem cell (iPSC) line had been generated from
human skin ﬁbroblasts of a male, symptomatic 52-year-old
spinocerebellar type 2 (SCA2) patient (anonymized as H196) using epi-
somal vectors carrying transcripts for human OCT4, SOX2, KLF4, L-MYC,
LIN28, and small hairpin RNA for TP53 (Okita et al. 2011). This cell line,
H196 clone (c) 7, has beendescribed as a bona ﬁde iPSC linewith a normal
karyotype (Marthaler et al., submitted to Stem Cell Research).
We have generated a gene-corrected clone of H196 c7 using the
CRISPRs/Cas9 system (Ran et al. 2013), where the expanded 36 CAG re-
gion in the ATXN2 gene has been replaced with a wildtype 22 CAG re-
peat (Fig. 1A). Successful exchange was validated by sequencing (Fig.
1B). We have furthermore conﬁrmed that the DNA sequence stayed in-
tact and no frameshift or other mutation had been introduced into the
gene edited site, by analyzing the region around the CRISPR cutting
site (nucleotide 119–141 in Fig. 1A).
Subsequently, we conﬁrmed that the gene corrected clone of H196
c7, termed H196 c7 GC, remained truly pluripotent. This was demon-
strated by expression of key pluripotency markers on RNA, as well as
protein level (Fig. 1C and D ). Additionally, H196 c7 GC retained the po-
tential to differentiate into cell types of the three germ layers upon em-
bryoid body formation (Fig. 1E). More importantly, no genetic
chromosomal aberrations were introduced by the gene editing process
and the cells still exhibit a normal karyotype (Fig. 1F).C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (caption on page 164).
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line of an existing SCA2 iPSC line. Together with two more SCA2
patient-derived iPSC lines and their corresponding isogenic, gene-
corrected controls (Marthaler et al., submitted to Stem Cell Research),
they will serve as an ideal study tool for in vitro disease modeling of
SCA2.O
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3.1. CRISPR design
Isogenic gene-corrected controls were obtained using the
CRISPRs/Cas9 system in combination with a homologous construct
in the pEasy Flox II vector. CRISPRs targeting each site of the CAG
repeat of the ATXN2 locus were designed at http://crispr.mit.edu/.
The CRISPRs were generated following the protocol from Ran et al.
(Ran et al. 2013) in a single plasmid containing both sgRNA and the
Cas9 (Addgene plasmid ID 48139).A
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iPSCs growing on dishes coated with matrigel (Corning Biosci-
ence) in E8 medium (Gibco) were detached using Accutase
(Gibco). 106 cells were co-nucleofected with 2 μg of each CRISPR/
Cas9 plasmid and 1 μg of the resistance marker using the Amaxa 4D
Nucleofector (program CA167) and P3 Primary Cell Kit according to
the manufacturer's instructions (Lonza). iPSCs were subsequently
transferred back to a matrigel-coated dish in E8 medium
supplemented with 1 mM ROCK inhibitor (Sigma). 24 h post
nucleofection, cells were subjected to neomycin selection and
allowed to recover for a week. Resistant colonies were then picked
and expanded for genotyping.3.3. Genotyping
DNA for genotypingwas extracted using the FlexiGene Kit (Qiagen).
PCR genotypingwas performed using TEMPase Hot Start DNA Polymer-
ase (Ampliqon) according to the manufacturer's instructions at an an-
nealing temperature of 58 °C. The following primers were designed
300 base pairs up- and downstream of the CRISPR cutting site to ensure
detection of insertion at homologous site: SCA2 long1 forward 5′-CAGA
CCCGCCTTGAGGAAG-3′ and SCA2 long1 reverse 5′-GAGGAGACCGAG
GACGAGG-3′. Clones where the expanded SCA2 allele was successfully
replacedwith theATXN2wildtype constructwere subjected to sequenc-
ing to exclude introduction of frameshifts or other mutations.3.4. Sequencing
Sanger sequencing of a 300 base pair region around the CAG repeat
region of the ATXN2 gene was carried out in an ABI PRISM 310 Genetic
Analyzer using the primers SCA2 seq2 forward 5′-CTTGGTCTCGGCGG
GC-3′ and SCA2 seq2 reverse 5′-GAGGAGACCGAGGACGAGG-3′.Fig. 1. The gene-corrected H196 c7 GC is a bona ﬁde iPSC line with a normal karyotype. (A)
(B) Simultaneous sequencing of both ATXN2 alleles showing 22 CAGs, highlighted in blue. The
TRA1–60, and SSEA4 immunoﬂuorescence images of H196 c7 GC, counterstained with Hoechs
Data were plotted relative to H1 human ESCs. Fibroblasts served as a negative control. Erro
housekeeping genes, ACTB, RPL37a, HSP90AB1, and GAPDH. (E) Immunocytochemistry fo
(mesoderm), and AFP (endoderm), after in vitro differentiation of H196 c7 GC by embryoid
normal 46, XY karyotype.3.5. RNA extraction, cDNA synthesis, and quantitative real-time PCR (qRT-
PCR)
RNA was extracted using RNeasy Mini (QIAGEN) and cDNA synthe-
sis was performed using Revert Aid First Strand cDNA synthesis kit
(Thermo Scientiﬁc) according to the manufacturers' protocols. qRT-
PCR was carried out using LightCycler 480 SYBR Green I Master
(Roche). Data was plotted using the delta delta Ct algorithm, 2(−ΔΔCt).
The following primers were used:Sch
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formation. Scale bars, 100 μm. (5′-CCCCAGGGCCCCATTTTGGTACC-3′
CT4 rev 5′-ACCTCAGTTTGAATGCATGGGAGAGC-3′
X2 for 5′-TTCACATGTCCAGCACTACCAGA-3′
X2 rev 5′-TCACATGTGTGAGAGGGGCAGTGTGC-3′
ANOG for 5′-AAAGAATCTTCACCTATGCC-3′
ANOG rev 5′-GAAGGAAGAGGAGAGACAGT-3′
EX1 for 5′-TTTCTGAGTACGTGCCCAGGCAA-3′
EX1 rev 5′-CTCTGAGAAAGCATCTCTCCTTC-3′
N28 for 5′-AGCCATATGGTAGCCTCATGTCCGC-3′
N28 rev 5′-TCAATTCTGTGCCTCCGGGAGCAGGGTAGG-3′
CTB for 5′-TCAAGATCATTGCTCCTCCTGAG-3′
CTB rev 5′-ACATCTGCTGGAAGGTGGACA-3′
PL13A for 5′-TTCCAAGCGGCTGCCGAAGA-3′
PL13A rev 5′-TTCCGGCCCAGCAGTACCTGT-3′
SP90AB1 for 5′-TCCGGCGCAGTGTTGGGAC-3′
SP90AB1 rev 5′-TCCATGGTGCACTTCCTCAGGC-3′
APDH for 5′-CTGGTAAAGTGGATATTGTTGCCAT-3′
APDH rev 5′-TGGAATCATATTGGAACATGTAAACC-3′G3.6. Immunocytochemistry
Immunocytochemistry was performed as previously described
(Marthaler et al. 2013). The following primary antibodies were used:
Anti-OCT4 (Santa Cruz, sc 8628); anti-NANOG (Peprotech, 500P236);
anti-TRA1–60 (BioLegend, 330,602); anti-SSEA4 (BioLegend, 330,402);
anti-TUBB3 (Millipore, MAB1637); anti-SMA (Dako, M0851), anti-AFP
(Dako, A0008); all 1:500. Secondary antibodies used were: Alexa Fluor
488 donkey anti-rabbit (A21206), donkey anti-goat (A11055), and
goat anti-mouse (A11017), all 1:2000 (Invitrogen).3.7. Embryoid body differentiation
iPSCs growing in E8 medium (Gibco) on matrigel (Corning Biosci-
ence) were dissociated with EDTA (Gibco) and allowed to form aggre-
gates in none-coated cell culture dishes. On day 3, aggregates were
transferred to matrigel-coated dishes andmediumwas switched to dif-
ferentiation medium: DMEM/F12 containing 20% FBS, L-glutamine, and
non-essential amino acids (all Gibco) for meso- and endoderm induc-
tion, or DMEM/F12 containing 50% neurobasal medium, B27, N2, and
L-glutamine (all Gibco) for ectoderm induction. Cells were ﬁxed for im-
munocytochemistry on day 14.3.8. Veriﬁcation and authentication
An intact genome was demonstrated by karyotyping using G-
banding (Fig. 1F). Analysiswas performed at the Institute ofMedical Ge-
netics and Applied Genomics, University of Tübingen, Tübingen,
Germany.ne editing strategy using the CRISPR/Cas9 system.
AG repeat is indicated in yellow. (C) OCT4, NANOG,
levels of pluripotency genes measured by qRT-PCR.
ulations based on ΔΔCt-values obtained from four
the three germ layers, TUBB3 (ectoderm), SMA
F) Chromosome analysis of H196 c7 GC showing a
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